These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29600194)

  • 21. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.
    Kouroukli O; Bravou V; Giannitsas K; Tzelepi V
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in
    Watson AP; Shabaneh A; Wang J; Dehm SM; Rao A; Ryan CJ
    Am J Clin Exp Urol; 2020; 8(4):106-115. PubMed ID: 32929406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1
    Kwon OJ; Zhang L; Jia D; Xin L
    Oncogene; 2021 Jan; 40(1):203-214. PubMed ID: 33110232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc.
    Kwon OJ; Zhang L; Jia D; Zhou Z; Li Z; Haffner M; Lee JK; True L; Morrissey C; Xin L
    Oncogene; 2020 Nov; 39(48):7142-7151. PubMed ID: 33009488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Francis JC; Capper A; Ning J; Knight E; de Bono J; Swain A
    Oncotarget; 2018 Jan; 9(7):7604-7615. PubMed ID: 29484136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
    Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
    Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
    Soundararajan R; Viscuse P; Pilie P; Liu J; Logotheti S; Laberiano Fernández C; Lorenzini D; Hoang A; Lu W; Soto LMS; Wistuba II; Xu M; Song X; Shepherd PDA; Navone NM; Tidwell RSS; Lozano G; Logothetis C; Zhang J; Long JP; Estecio MR; Tzelepi V; Aparicio AM
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.
    Jindal R; Nanda A; Pillai M; Ware KE; Singh D; Sehgal M; Armstrong AJ; Somarelli JA; Jolly MK
    Comput Struct Biotechnol J; 2023; 21():1498-1509. PubMed ID: 36851919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lineage Plasticity in Cancer: The Tale of a Skin-Walker.
    Thankamony AP; Subbalakshmi AR; Jolly MK; Nair R
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
    Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
    Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.
    German B; Singh JN; Fonseca MA; Burkhart DL; Sheahan A; Bergom H; Morel KL; Beltran H; Hwang JH; Lawrenson K; Ellis L
    bioRxiv; 2024 Feb; ():. PubMed ID: 38352340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
    Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
    Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.